HTML Microdata document

This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n21	http://linked.opendata.cz/resource/drugbank/drug/DB00866/identifier/chemspider/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n8	http://linked.opendata.cz/resource/mesh/concept/
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00866/identifier/chebi/
foaf	http://xmlns.com/foaf/0.1/
n24	http://linked.opendata.cz/resource/drugbank/drug/DB00866/identifier/wikipedia/
n23	http://linked.opendata.cz/resource/drugbank/drug/DB00866/identifier/pharmgkb/
n10	http://bio2rdf.org/drugbank:
n14	http://linked.opendata.cz/resource/drugbank/drug/DB00866/identifier/bindingdb/
n19	http://linked.opendata.cz/resource/drugbank/drug/DB00866/identifier/pubchem-compound/
adms	http://www.w3.org/ns/adms#
n22	http://linked.opendata.cz/resource/drugbank/drug/DB00866/identifier/pubchem-substance/
n12	http://linked.opendata.cz/resource/drugbank/patent/
n4	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n25	http://linked.opendata.cz/resource/drugbank/drug/DB00866/identifier/kegg-drug/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n18	http://linked.opendata.cz/resource/drugbank/drug/DB00866/identifier/drugbank/
n7	http://linked.opendata.cz/ontology/mesh/
n9	http://linked.opendata.cz/ontology/drugbank/
owl	http://www.w3.org/2002/07/owl#
n11	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n6	http://www.drugs.com/international/
n16	http://linked.opendata.cz/resource/atc/
n15	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00866
rdf:type: n9:Drug
n9:description: One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.
n9:generalReferences: # Hold KM, de Boer D, Bos KL, van Ooijen RD, Zuidema J, Maes RA: Enantioselective quantitation of (R)- and (S)-alprenolol by gas chromatography-mass spectrometry in human saliva an plasma. J Chromatogr Sci. 1996 Jan;34(1):13-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8586675 # Himori N, Ishimori T, Izumi A, Hiramatsu Y: Effects of beta-adrenoceptor blocking agents, pindolol, alprenolol and practolol on blood pressure and heart rate in conscious renal hypertensive dogs. Arch Int Pharmacodyn Ther. 1977 Jan;225(1):152-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15525
n9:group: withdrawn approved
n9:halfLife: 2-3 hours
n9:indication: For the treatment of hypertension, angina, and arrhythmia
owl:sameAs: n4:DB00866 n10:DB00866
dcterms:title: Alprenolol
adms:identifier: n14:25764 n18:DB00866 n19:2119 n20:51211 n21:2035 n22:46506033 n23:PA164750541 n24:Alprenolol n25:D07156
n9:mechanismOfAction: Alprenolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. Also, with a more minor effect, by binding beta-2 receptors in the juxtaglomerular apparatus, alprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
n9:patent: n12:3466376
n9:synonym: Aprenololo 1-(2-Allylphenoxy)-3-isopropylamino-2-propanol (RS)-1-(2-allylphenoxy)-3-(isopropylamino)propan-2-ol Alprenololum Alprénolol 1-(O-Allylphenoxy)-3-(isopropylamino)-2-propanol Alprenolol Alfeprol
n9:toxicity: LD<sub>50</sub>=597.0 mg/kg (Orally in rats)
n9:proteinBinding: 80-90%
n9:salt
n9:synthesisReference: http://www.google.com.mx/patents/US3466376
n7:hasConcept: n8:M0000809
foaf:page: n6:alprenolol.html
n9:IUPAC-Name: n11:271B5256-363D-11E5-9242-09173F13E4C5
n9:InChI: n11:271B525C-363D-11E5-9242-09173F13E4C5
n9:Molecular-Formula: n11:271B525B-363D-11E5-9242-09173F13E4C5
n9:Molecular-Weight: n11:271B5258-363D-11E5-9242-09173F13E4C5
n9:Monoisotopic-Weight: n11:271B5259-363D-11E5-9242-09173F13E4C5
n9:SMILES: n11:271B525A-363D-11E5-9242-09173F13E4C5
n9:Water-Solubility: n11:271B526C-363D-11E5-9242-09173F13E4C5 n11:271B5254-363D-11E5-9242-09173F13E4C5
n9:logP: n11:271B526E-363D-11E5-9242-09173F13E4C5 n11:271B5255-363D-11E5-9242-09173F13E4C5 n11:271B5252-363D-11E5-9242-09173F13E4C5
n9:logS: n11:271B5253-363D-11E5-9242-09173F13E4C5
n15:hasATCCode: n16:C07AA01
n9:H-Bond-Acceptor-Count: n11:271B5262-363D-11E5-9242-09173F13E4C5
n9:H-Bond-Donor-Count: n11:271B5263-363D-11E5-9242-09173F13E4C5
n9:InChIKey: n11:271B525D-363D-11E5-9242-09173F13E4C5
n9:Polar-Surface-Area--PSA-: n11:271B525E-363D-11E5-9242-09173F13E4C5
n9:Polarizability: n11:271B5260-363D-11E5-9242-09173F13E4C5
n9:Refractivity: n11:271B525F-363D-11E5-9242-09173F13E4C5
n9:Rotatable-Bond-Count: n11:271B5261-363D-11E5-9242-09173F13E4C5
n9:affectedOrganism: Humans and other mammals
n9:caco2-Permeability: n11:271B526F-363D-11E5-9242-09173F13E4C5
n9:casRegistryNumber: 13655-52-2
n9:category
n9:Bioavailability: n11:271B5268-363D-11E5-9242-09173F13E4C5
n9:Ghose-Filter: n11:271B526A-363D-11E5-9242-09173F13E4C5
n9:MDDR-Like-Rule: n11:271B526B-363D-11E5-9242-09173F13E4C5
n9:Melting-Point: n11:271B526D-363D-11E5-9242-09173F13E4C5
n9:Number-of-Rings: n11:271B5267-363D-11E5-9242-09173F13E4C5
n9:Physiological-Charge: n11:271B5266-363D-11E5-9242-09173F13E4C5
n9:Rule-of-Five: n11:271B5269-363D-11E5-9242-09173F13E4C5
n9:Traditional-IUPAC-Name: n11:271B5257-363D-11E5-9242-09173F13E4C5
n9:pKa--strongest-acidic-: n11:271B5264-363D-11E5-9242-09173F13E4C5
n9:pKa--strongest-basic-: n11:271B5265-363D-11E5-9242-09173F13E4C5